Nothing Special   »   [go: up one dir, main page]
Jump to content

1-Methylpsilocin

Add links
From Wikipedia, the free encyclopedia
1-Methylpsilocin
Clinical data
Other namesCMY; CMY-16; 3-(2-(Dimethylamino)ethyl)-1-methyl-indol-4-ol
Identifiers
  • 1-Methyl-3-[2-(N,N-dimethylamino)ethyl]-4-hydroxyindole
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H18N2O
Molar mass218.300 g·mol−1
3D model (JSmol)
  • CN(C)CCc(cn1C)c2c1cccc2O
  • InChI=1S/C13H18N2O/c1-14(2)8-7-10-9-15(3)11-5-4-6-12(16)13(10)11/h4-6,9,16H,7-8H2,1-3H3
  • Key:MZZRFEIDRWKTKJ-UHFFFAOYSA-N

1-Methylpsilocin (developmental code names CMY, CMY-16) is a tryptamine derivative developed by Sandoz which acts as a selective agonist of the serotonin 5-HT2C receptor (IC50Tooltip half-maximal inhibitory concentration of 12 nM, vs. 633 nM at 5-HT2A), and an inverse agonist at 5-HT2B (Ki of 38 nM). While 1-methylpsilocin does have higher affinity for 5-HT2C than 5-HT2A, it does produce a head-twitch response in mice that is dependent on 5-HT2A, so it is not entirely free of effects on 5-HT2A in vivo. In contrast to psilocin, 1-methylpsilocin did not activate 5-HT1A receptors in mice.[1][2][3]

1-Methylpsilocin has been investigated for applications such as treatment of glaucoma, obsessive–compulsive disorder (OCD), and cluster headaches, as these conditions are amenable to treatment with psychedelic drugs but are not generally treated with such agents due to the hallucinogenic side effects they produce, which are considered undesirable. 1-Methylpsilocin therefore represents a potential alternative treatment to psilocin that may be less likely to produce hallucinogenic effects.[1][2][3]

See also

[edit]

References

[edit]
  1. ^ a b Sard H, Kumaran G, Morency C, Roth BL, Toth BA, He P, Shuster L (October 2005). "SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist". Bioorganic & Medicinal Chemistry Letters. 15 (20): 4555–4559. doi:10.1016/j.bmcl.2005.06.104. PMID 16061378.
  2. ^ a b Sewell RA, Halpern JH, Pope HG (June 2006). "Response of cluster headache to psilocybin and LSD". Neurology. 66 (12): 1920–1922. doi:10.1212/01.wnl.0000219761.05466.43. PMID 16801660. S2CID 31220680.
  3. ^ a b Halberstadt AL, Koedood L, Powell SB, Geyer MA (November 2011). "Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice". Journal of Psychopharmacology. 25 (11): 1548–1561. doi:10.1177/0269881110388326. PMC 3531560. PMID 21148021.


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=1-Methylpsilocin&oldid=1244198646"